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Article focus
  Guidelines from The National Institute for 
health and care Excellence recommend 
bisphosphonates for all patients over 50 
at risk of, and those under 50 with a his-
tory of, fragility fracture. however, its use 
has been linked to atypical fractures of 
the femur (aFFs). This article aims to pro-
vide a summary of the current evidence 
linking bisphosphonate use to aFFs, 
while presenting current strategies for 
their treatment and prevention.
Key messages
  Bisphosphonates have been shown to 
increase microdamage accumulation and 
alter both bone mineralisation and colla-
gen formation.
  It is thought that these mechanisms con-
tribute to aFFs.
  little is known about risk factors for 
 bisphosphonate-related aFFs, and future 
studies should focus on identifying at-risk 
subpopulations.
Strengths and limitations
  our MEDlINE search is readily repro-
ducible, using clear and robust search 
terms.
  our article comprehensively addresses all 
aspects of pathogenesis and manage-
ment of aFFs related to the use of 
bisphosphonates.
  The limitation of electronic databases 
means that this may not include all avail-
able literature.
Bisphosphonates and atypical 
subtrochanteric fractures of the femur
Objectives
Bisphosphonates are widely used as first-line treatment for primary and secondary preven-
tion of fragility fractures. Whilst they have proved effective in this role, there is growing 
concern over their long-term use, with much evidence linking bisphosphonate-related sup-
pression of bone remodelling to an increased risk of atypical subtrochanteric fractures of the 
femur (AFFs). The objective of this article is to review this evidence, while presenting the 
current available strategies for the management of AFFs.
Methods
We present an evaluation of current literature relating to the pathogenesis and treatment of 
AFFs in the context of bisphosphonate use.
Results
six broad themes relating to the pathogenesis and management of bisphosphonate-related 
AFFs are presented. The key themes in fracture pathogenesis are: bone microdamage accu-
mulation; altered bone mineralisation and altered collagen formation. The key themes in 
fracture management are: medical therapy and surgical therapy. In addition, primary pre-
vention strategies for AFFs are discussed.
Conclusions
This article presents current knowledge about the relationship between bisphosphonates 
and the development of AFFs, and highlights key areas for future research. In particular, 
studies aimed at identifying at-risk subpopulations and organising surveillance for those on 
long-term therapy will be crucial in both increasing our understanding of the condition, and 
improving population outcomes.
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Introduction
osteoporosis, a condition associated with significant mor-
bidity and mortality, results in patients having an increased 
risk of fractures. Bisphosphonates are a class of drug com-
monly prescribed to mitigate this risk. approximately 50% 
of women over the age of 50 sustain an osteoporosis-
related fracture or a fragility fracture during their lifetime, 
and one in five patients die within 12 months of the frac-
ture.1-4 clinical trials of bisphosphonates have demon-
strated a significant decrease in the incidence of spinal 
and hip fractures and a concomitant reduction in associ-
ated costs and healthcare utilisation.5-12 Subsequent sys-
tematic reviews have supported the use of bisphosphonates 
as first-line treatment for primary and secondary preven-
tion of fragility fractures in women, as well as the preven-
tion and treatment of steroid-induced osteoporosis.13-16 
however, despite their success, there has been growing 
concern over the long-term use of bisphosphonates. This 
is predominantly due to reports of increased risk of atypi-
cal subtrochanteric fractures of the femur (aFFs), which 
are thought to be secondary to bisphosphonate-related 
suppression of bone remodelling.17 The first such case 
series was published in 2005 and described aFFs and 
other non-vertebral fractures in nine adults following 
three to eight years of alendronate therapy.18 The frac-
tures were atraumatic, and occurred earlier in the treat-
ment period when alendronate was co-administered with 
either glucocorticoids or oestrogen. Since then, there has 
been a surge in published reports describing similar cases 
and investigating the association on a large scale, with 
one nationwide cohort study in Sweden finding the age-
adjusted relative risk of aFFs with any use of bisphospho-
nates to be 47.3.19-26
In 2009, in response to the reported association 
between bisphosphonates and aFFs, the leadership of 
the american Society for Bone and Mineral research 
(aSBMr) appointed a task force to address key questions 
relating to this problem.17 a multidisciplinary expert 
group reviewed pertinent published reports concerning 
aFFs, as well as preclinical studies that could provide 
insight into their pathogenesis. The task force defined 
major and minor features for complete and incomplete 
aFFS, which were updated in 2013 (Table I).27 The report 
recommended that in order to designate a fracture of the 
femur as atypical, at least four of five major features must 
be present. conversely, minor features, despite being 
commonly associated with atypical fractures, are not 
required for the diagnosis. The aSBMr task force exam-
ined 310 case reports, of which 291 (94%) identified bis-
phosphonate use as a comorbidity, with a mean treatment 
duration of seven years. Despite this work, much uncer-
tainty continues to surround the pathogenesis of these 
fractures, and their relative infrequency precludes wide-
spread knowledge of the optimum management. The 
objective of this article is to review this evidence, whilst 
presenting the current available strategies for the man-
agement of bisphosphonate-related aFFs.
Materials and Methods
We conducted a literature search of journal articles using 
the MEDlINE, Embase, cochrane library and Google 
Scholar databases in June 2016. No date restrictions were 
placed on the search. We used the key words ‘bisphospho-
nates atypical fracture’, ‘bisphosphonates subtrochanteric 
fracture’, ‘bisphosphonate mechanism’, ‘bisphospho-
nate bone healing’, ‘bisphosphonate microfracture’, ‘bis-
phosphonate collagen’, ‘bisphosphonate complications’, 
‘subtrochanteric femoral fracture’ and ‘subtrochanteric 
fracture treatment’.
From the search results, articles with irrelevant titles 
were discounted, with the remaining abstracts examined 
for relevance. reference listings of the remaining articles 
were also searched and scrutinised for relevance. The ref-
erence list generated was modified during the peer-
review process in accordance with comments from the 
reviewers.
Mechanism of action of bisphosphonates. Bisphosphonates 
contain a backbone of two phosphonate groups cova-
lently bonded to a central carbon atom, which in turn has 
two side chains (r1 and r2) that determine the chemical 
properties of the compound. They are carbon-substituted 
analogues of pyrophosphate, a ubiquitous molecule used 
in biochemical reactions throughout the body. like pyro-
phosphate, bisphosphonates bind to hydroxyapatite and 
are thus absorbed by bone. Investigation of this binding 
mechanism led to the initial theory, proposed by Fleisch 
et al in 1969, that bisphosphonates achieve inhibition of 
bone resorption by reducing hydroxyapatite dissolution.28 
however, subsequent structure-activity relation studies 
showed no close correlation between the levels of hydroxy-
apatite binding and inhibition of resorption, giving rise to 
the theory that bisphosphonates act directly on bone cells 
(Fig. 1).29 Proposed mechanisms of action include:
- cytotoxic or metabolic injury of mature 
osteoclasts;30,31
- inhibition of osteoclast attachment to bone;32
- inhibition of osteoclast differentiation or 
recruitment;33-37
- interference with osteoclast structural features 
(cytoskeleton), necessary for bone resorption.38-40
although all bisphosphonates concentrate in, and 
therefore selectively act on, bone, their mechanism of 
action may differ according to their side chains.29 Sato 
et al35 examined the association of alendronate (4-amino-
1-hydroxybutylidene-1, 1-biphosphonic acid) with bone 
particles and its localisation in rat bone at one and six 
days after injection. They subsequently examined its 
effects on: osteoclast ultrastructure in situ; rat and chicken 
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osteoclast resorption in vitro; and osteoclast intracellular 
calcium and cyclic adenosine monophosphate levels. 
Their findings suggested that alendronate binds to 
resorption surfaces and is locally released during subse-
quent osteoclastic acidification, preventing bone resorp-
tion and membrane ruffling without destroying the 
osteoclasts.
Masarachia et al41 noted the predilection of alendro-
nate for osteoclasts over osteoblasts at a ratio of 8:1. In 
addition, they demonstrated the presence of alendronate 
deep within the mineralised matrix, where it lies dor-
mant, activated only during osteoclastic acidification to 
prevent resorption.
Further structural refinement led to the creation of two 
further subclasses of bisphosphonates: nitrogen contain-
ing (NBP); and non-nitrogen containing (NNBP) bisphos-
phonates. This prompted further investigation into the 
mechanism of action of bisphosphonates at the molecu-
lar level. It was found that these two subclasses utilise 
two different pathways to produce their effects. The 
NNBP subclass (etidronate, tiludronate) affects bone 
resorption through its metabolites, which form toxic aTP 
analogues that induce osteoclast apoptosis. The NBP 
subclass (alendronate, ibandronate, pamidronate, rise-
dronate, and zoledronate) inhibits the mevalonate path-
way, a fundamental metabolic pathway in eukaryotes 
and bacteria that plays a key role in osteoclast formation 
and function, through their inhibition of farnesyl diphos-
phate synthase (a tyrosine phosphatase).42-51
Pathogenesis of bisphosphonate-related AFFs. Despite 
the beneficial effects of bone turnover suppression on 
bone strength, severe suppression of bone turnover by 
bisphosphonates is thought to play a major role in the 
development of aFFs. current estimates place the age-
adjusted relative risk of an aFF with any use of bisphos-
phonates at 47.3, with risk of fracture increasing over 
time from ten times the baseline after two years of ther-
apy to 50 times the baseline thereafter. current estimates 
of the number needed to harm are 2000 per year use, 
with 78% of aFFs associated with bisphosphonate use.19
The accumulation of bisphosphonates at sites of high 
osteogenic activity, such as areas of microfracture repair, 
can result in a local amplification of their effects, leading 
to potentially pathogenic changes in bone mineralisa-
tion, collagen cross-linking and the mineral and organic 
matrix.51 The following is a list of possible pathogenic 
mechanisms for aFFs, as suggested by Shane et al:17
“- Microdamage accumulation
- changes to bone mineralisation, including 
increased mineralisation and reduced heterogene-
ity of mineralisation
- alterations to the normal pattern of collagen cross-
linking, either due to changes to the maturity of 
cross-links formed by enzymatic processes or 
advanced glycation end-product accumulation
- variations in rates of bone turnover
- reduced vascularity
- anti-angiogenic effects.”
The effect of bisphosphonates on microdamage accumu-
lation. In normal bone, microdamage caused by cyclic 
loading is a natural physiologic event that initiates bone 
remodelling. It accumulates in states of reduced bone 
turnover, as is found physiologically in advanced age.52 
Bone treated with bisphosphonate has an exaggerated 
reduction in bone turnover, and has been shown to 
gather microdamage exponentially over time.53,54 It is 
notable that a relatively small reduction in bone turnover 
is required to trigger this exponential increase in micro-
damage, with one study of risedronate showing a 40% 
slowing in turnover causing a three-fold increase in the 
volume of microdamage.55,56
Brennan et al57 used a sheep model of osteoporosis to 
examine the effects of bisphosphonates on osteocyte 
apoptosis and microdamage accumulation. They reported 
an increased number of micro cracks with bisphospho-
nate therapy in skeletally mature ewes. Despite this, there 
was no associated increase in the risk of fracture. Indeed, 
a direct link between bisphosphonate- associated 
Table I. atypical fracture of the femur: major and minor features27
Major features
- The fracture is associated with minimal or no trauma, as in a fall from a standing height or lower
-  The fracture line originates at the lateral cortex and is substantially transverse in its orientation, although it may become oblique as it progresses medially 
across the femur
- complete fractures extend through both cortices and may be associated with a medial spike; incomplete fractures involve only the lateral cortex
- The fracture is noncomminuted or minimally comminuted
- localised periosteal or endosteal thickening of the lateral cortex is present at the fracture site (“beaking” or “flaring”)
Minor features
- Generalised increase in cortical thickness of the femoral diaphysis
- Unilateral or bilateral prodromal symptoms such as dull or aching pain in the groin or thigh
- Bilateral incomplete or complete femoral diaphyseal fractures
- Delayed fracture healing
- comorbid conditions (e.g. vitamin D deficiency, rheumatoid arthritis, hypophosphataemia)
- Use of pharmaceutical agents (e.g. bisphosphonates, glucocorticoids, proton pump inhibitors)
147 Bisphosphonates and atypical suBtrochanteric fractures of the femur
Bone & Joint research
microdamage accumulation and atypical fractures is not 
yet established in humans. Furthermore, studies of iliac 
crest biopsies have provided conflicting data about 
whether the microdamage accumulates with bisphospho-
nate treatment in humans. one study evaluated women 
treated for an average of five years with alendronate, 
showing a significant increase in crack density in the treat-
ment group when compared with a treatment-naïve 
group.58 however, these results were contradicted by a 
second study of a comparable population which showed 
no association between bisphosphonate treatment and 
microdamage accumulation in the iliac crest.59 Neither of 
these studies evaluated samples from the femoral cortex 
and, because the accumulation of microdamage is site-
specific, the effect on microdamage in the femoral diaphy-
sis is currently unknown.
The effect of bisphosphonates on bone mineralisation.  
The suppression of bone turnover alters bone mineral 
and matrix properties. Bisphosphonates prolong the 
life of existing bone remodelling units and reduce the 
formation of new ones. This prolongation allows for a 
greater percentage of bone remodelling units to become 
older and fully mineralised, leading to an increase in 
the homogeneity of mineralisation. although increased 
mineralisation results in increased strength and stiffness 
of the bone, it also results in more brittle bone which 
is consequently more susceptible to fracture.60 Boskey 
et al61 used infrared spectroscopic imaging to investigate 
the material properties of iliac crest biopsies taken from 
seven  alendronate-treated women and ten age-matched 
controls. The group showed that whilst alendronate 
treatment increases bone mass, it decreases tissue hetero-
geneity, which could impair tissue mechanical properties.
healthy, heterogeneous bone contains areas of vary-
ing compliance and stiffness, which can halt the propa-
gation of microfractures. In bisphosphonate-exposed 
bone, increased homogeneity in the organic matrix, com-
bined with the increased homogeneity of mineralisation, 
may allow further propagation of micro cracks, leading 
to a higher fracture risk.
The effect of bisphosphonates on collagen. collagen, 
which constitutes 90% of the organic matrix of bone, is 
cross-linked both enzymatically and non-enzymatically. 
The enzymatic process is mediated by lysyl and prolyl 
hydroxylases, resulting in the trivalent collagen cross-
links. These cross-links yield a more stable collagen matrix 
and seem to be positively associated with stiffness and 
strength in bone.62,63 Saito et al64 used a canine model 
to show that the total number of enzymatic cross-links is 
unaffected by three years of bisphosphonate treatment. 
Non-enzymatic cross-linking, on the other hand, occurs 
when reducing sugars interact with free amino groups in 
collagen, resulting in advanced glycation end products 
(aGEs). Increased aGE concentration in bone has been 
shown to significantly increase the brittleness of bone.62 
Bisphosphonates suppress bone turnover, increasing 
mean tissue age. as the concentration of aGEs within 
bone increases over time, it is thought that aGE con-
centration is increased within bisphosphonate-treated 
bone. Multiple canine studies have shown that one to 
three years of treatment with bisphosphonate results in 
increased aGE concentration in bone.63,64 There is cur-
rently no human data on the accumulation of aGEs in 
patients who are undergoing long-term bisphosphonate 
therapy, thus the extent to which they accumulate in 
patients remains unclear.
Epidemiology of AFFs. Many epidemiological studies 
have sought to clarify the relationship between bisphos-
phonate use and aFFS, with varying results. Such studies 
broadly fall into two categories: smaller studies utilising 
radiographs to categorise fractures; and larger studies 
using registry data complete with fracture classification 
(either subtrochanteric (ST) or femoral shaft (FS)).27 Most 
studies using registry data have found no change in 
the rates of subtrochanteric or fractures of the femoral 
shaft since the use of bisphosphonates for osteoporosis 
prevention and treatment was approved.65-71 however, 
these studies are limited firstly by the fact that not all ST 
and FS fractures are atypical, and secondly by the poor 
sensitivity and specificity of registry data.72,73 conversely, 
the majority of studies utilising radiographic data have 
shown a strong association between bisphosphonates 
HMG-CoA
Mevalonate
Phosphomevalonate
Mevalonate-diphosphate
Isopentenyldiphosphate Dimethylallyldiphosphate
FFP synthase
Cholesterol Squalene Farnesyl-diphosphate
N-Bisphosphonates
Geranylgeranyl-diphosphate
Geranylgeranylation
Osteoclast function Osteoclast survival
Fig. 1
Schematic illustration of pathway target of nitrogen-containing bisphos-
phonates (N-bisphosphonates) in the inhibition of osteoclast function and 
survival; N-bisphosphonates target and inhibit farnesyl diphosphate (FPP) 
synthase (data used to create figure taken from Fleisch29)
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and aFFs.19,22-25,26,74-82 These studies remain limited by 
their size and ability to accurately ascertain drug expo-
sure.82 The 2013 aSBMr task force reported that although 
a causal relationship was yet to be proven, the studies 
reporting a relationship between bisphosphonates and 
aFFs are consistent and robust.27
Risk factors for AFFS. There has been much recent focus 
on identifying risk factors for developing aFFs in patients 
receiving bisphosphonate therapy. a 2013 study by 
Franceschetti et al suggested that metabolic characteris-
tics may play a key role in fracture development.83 The 
group identified an inadequate response of parathyroid 
hormone to hypocalcaemia as the primary risk factor in 
these patients, and suggest obesity, early menopause and 
younger age (< 70 years) as other potential risk factors. 
Mechanical factors have also been identified as potential 
risk factors for development of an aFF. Taormina et al84 
analysed pre-fracture radiographs of 53 bisphosphonate 
users who went on to develop aFFs, and compared them 
with control radiographs and pre-fracture radiographs 
from patients who went on to sustain intertrochanteric 
fractures. The study revealed associations between neck-
shaft angle and centre-edge angle with development 
of aFF. although no current guidelines exist, the pres-
ence of these risk factors in patients receiving long-term 
bisphosphonate therapy should prompt consideration of 
surveillance for development of aFF.
Preventing bisphosphonate-related AFFs. There is con-
siderable controversy over the optimum duration of 
bisphosphonate therapy. concern surrounding aFFs, 
as well as osteonecrosis of the jaw, prompted the Food 
and Drug administration (FDa) to re-evaluate the efficacy 
of continuing bisphosphonate therapy beyond three to 
five years.85,86 Their review focused on three long-term 
extension trials — the Fosamax Fracture Intervention 
Trial long-Term (FlEX) extension; the reclast health 
outcomes and reduced Incidence with Zoledronic acid 
once Yearly–Pivotal Fracture Trial (horIZoNPFT) exten-
sion; and the actonel vertebral Efficacy with risedronate 
Therapy–Multinational Trial (vErT-MN) extension, in 
which the duration of treatment ranged from six to ten 
years.86 The FlEX trial randomly assigned 1099 post-
menopausal women, who had previously received an 
average of five years of daily alendronate therapy, to 
continued alendronate treatment or placebo for an addi-
tional five years.87 The horIZoNPFT extension trial used 
a similar design with a shorter treatment period (three 
years of treatment followed by three years of placebo or 
active extension).88 Both studies used changes in bone 
mineral density as their primary end points and reported 
fractures as exploratory end points. Both showed signifi-
cant reduction in the risk of vertebral fracture with con-
tinuation of bisphosphonate treatment.
Pooled data from the three extension trials specific to 
those patients who were treated with bisphosphonates for 
six years or more (2496 patients) showed vertebral and 
non-vertebral osteoporotic fracture rates of between 9.3% 
and 10.6%. By comparison, patients who were switched 
to the placebo for the extension period (starting at four 
years for alendronate and three years for risedronate and 
zolendronate) showed lower fracture rates of between 
8.0% and 8.8%.85 This raises the question of whether con-
tinued bisphosphonate therapy beyond three to five years 
imparts additional fracture-prevention benefit. This ques-
tion is further complicated by the observation that bone 
loss on cessation of bisphosphonate therapy is modest 
when alendronate and zolendronate are the agents of 
choice, whereas a much greater bone loss occurs upon the 
discontinuation of risedronate. No data are currently avail-
able post cessation of ibandronate therapy.89
overall, the evidence regarding this increased risk of 
fracture with continuation of bisphosphonate therapy 
beyond three to five years remains limited, with data from 
randomised controlled trials suggesting that an overall 
reduction in the risk of vertebral fractures persists. There 
does, however, remain a lack of consistent evidence that 
prolonged bisphosphonate therapy is associated with a 
significant reduction in non-vertebral fractures. This mat-
ter was addressed by Black et al in 2012,89 who made sev-
eral recommendations. Firstly, they recommend that 
patients with low bone mineral density at the femoral 
neck (T score below −2.5) after three to five years of treat-
ment are at the highest risk for vertebral fractures and 
therefore appear to benefit most from continuation of bis-
phosphonates. Secondly, patients with an existing verte-
bral fracture who have a somewhat higher (although not 
higher than −2.0) T score for bone mineral density may 
also benefit from continued therapy. Finally, patients with 
a femoral neck T score above −2.0 have a low risk of verte-
bral fracture and are unlikely to benefit from continued 
treatment. Unfortunately, a large proportion of patients 
are asymptomatic prior to developing a fracture, and the 
current literature has failed to establish clear surveillance 
guidelines for those on long-term bisphosphonate ther-
apy. Interval femoral radiograph monitoring may be used 
to identify early stress reactions/fractures, though this 
relies on experienced radiologists.84 Further investigation 
into the benefits and risks of long-term therapy, as well as 
surveillance of fracture risk after discontinuation of bis-
phosphonates, is needed to optimise outcomes for 
patients (Fig. 2).
Surgical management of bisphosphonate-related AFFs. The 
aSBMr task force recognised that there are no con-
trolled studies evaluating surgical treatment strategies 
for aFFs.27 Their recommendations, therefore, were 
opinion-based and represented the consensus of the 
orthopaedic surgeons who served on the task force. 
They developed a hierarchical approach to manage-
ment depending on whether the fracture is complete or 
incomplete (Fig. 3).27,90
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History of thigh or groin pain in a patient on bisphospho-
nate therapy. It is essential to rule out an impending frac-
ture of the femur in these patients with anteroposterior 
and lateral plain radiographs of the hip, including the full 
diaphysis of the femur. If the radiographs are normal but 
clinical suspicion remains high, a technetium bone scan 
or MrI of the femur should be performed. Bone marrow 
oedema is indicative of an active stress fracture, which 
should be managed conservatively with partial weight-
bearing, cessation of bisphosphonate therapy, calcium 
and vitamin D supplementation and the commencement 
of teriparatide.27 close follow-up with MrI is needed to 
monitor the resolution of bone marrow oedema and pre-
vent progression to complete fracture.27,51
Complete subtrochanteric/diaphyseal fracture of the 
femur. although no studies have examined different sur-
gical options for atypical fractures, intramedullary nails 
are preferred over other fixation devices as they offer bio-
logical and biomechanical advantages. Biologically, frac-
tures treated by intramedullary nail heal by endochondral 
ossification.91 although bisphosphonates do not impair 
the initial phase of fracture healing or the development of 
a proliferative callus, they do inhibit osteoclastic remod-
elling. This results in a longer remodelling phase and 
delays the transformation of the calcified cartilage callus 
to mature bone. however, the alternative surgical strat-
egy of using metal plates requires intramembranous bone 
healing, which is inhibited by bisphosphonates. From a 
biomechanical point of view, plates are inherently inferior 
to nails because of their more lateral position (longer lever 
arm on the proximal fixation) and their non–load sharing 
characteristics. Therefore overall, plate-screw constructs 
are not recommended for aFFs.16 a full-length intramed-
ullary nail should be used, and the medullary canal should 
be over-reamed to facilitate insertion of the reconstruc-
tion nail and to prevent fracture of the remaining shaft. 
Irrespective of symptoms, the contralateral femur must be 
evaluated radiographically for the presence of a fracture.22
outcomes for complete aFFs are generally poor, with 
some studies showing 53% requiring revision after the 
initial intramedullary nailing.92 Saleh et  al52 proposed 
that pre-emptive autologous bone marrow grafting can 
be considered although, at present, no studies have 
examined the efficacy of this procedure in aFFs.
–  Continue bisphosphonate
therapy
–  Inadequate response of
    parathyroid hormone
    hypocalcaemia
–  Obesity
–  Early menopause
–  Younger age (< 70 yrs)
–  Varus neck-shaft angle and
    narrow centre-edge angle
–  Discontinue therapy
T Score < −2.5
Role for surveillance
Physiological risk factors:
Mechanical risk factors
T score > −2.0
Assessment (3 to 5 yrs)
–  Continue bisphosphonate therapy
−2.5 < T Score < −2.0 AND
existing vertebral fracture
Fig. 2
Flow chart showing possible pathway for prevention of bisphosphonate-related atypical fractures of the femur (data used to create figure taken from Shane 
et al27).
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Incomplete subtrochanteric/femoral shaft fractures. The 
management of incomplete atypical fractures depends 
on several factors, including symptoms, plain radio-
graphs, and MrI. For incomplete fractures accompanied 
by pain, prophylactic intramedullary nail fixation is rec-
ommended.19-22,88,89 Femoral radiographs with cortical 
thickening and stress reaction should be examined for 
the presence of a radiolucent fracture line across the lat-
eral cortex, which is a poor prognostic indicator warrant-
ing prophylactic fixation with an intramedullary nail.80 
For patients with incomplete fractures and no pain, lim-
ited weight bearing and avoidance of vigorous activity is 
advised until a surveillance MrI shows no bone oedema.
Medical management of bisphosphonate-
related AFFs
Discontinuing bisphosphonates. a large observational 
study, from a health maintenance organisation in 
california, examined the occurrence of a contralateral 
aFF following an index atypical fracture in patients who 
either continued or discontinued the use of bisphospho-
nates.93 Dell et  al75 showed the incidence of bilateral 
aFFs to be 41% in patients who continued bisphospho-
nates for three or more years after the index aFF, com-
pared with 19% in patients who discontinued the drug. 
Similarly, Schilcher et  al19 demonstrated that following 
atypical fracture, discontinuing bisphosphonate therapy 
achieved a 70% per-year reduction in the relative risk of 
developing contralateral atypical fracture. as a result, the 
International osteoporosis Foundation Fracture Working 
Group has recently recommended that bisphosphonate 
therapy be ceased following an aFF.94
Calcium and vitamin D supplementation. Dietary cal-
cium and vitamin D status should be assessed, and 
adequate supplementation prescribed if necessary, as 
this reduces the risk of all fractures by 12% to 26%.95-97 
recommendations for optimal treatment should include 
daily intakes of 1000 mg/day to 1200 mg/day of calcium 
and a minimum of 1000 IU to 2000 IU of vitamin D3, 
along with regular monitoring of serum 25-hydroxyvita-
min D and parathyroid hormone (PTh) levels.98,99
Teriparatide (1–34 PTH). Teriparatide, recombinant PTh 
1–34 (1–34 PTh), should be considered in patients with 
aFFs.51 It improves bone turnover and microarchitec-
ture in patients on long-term alendronate treatment and 
enhances fracture healing by increasing callus formation 
and mechanical strength.100-105 Two clinical trials also 
showed that teriparatide shortened the healing time in 
patients with osteoporotic fractures.106 although no ran-
domised studies exist to examine the effect of teriparatide 
in atypical fractures, the above studies provide a robust 
argument for its use in these patients.
In conclusion, although there is evidence of a relation-
ship between long-term use of bisphosphonates and a 
specific type of subtrochanteric and fracture of the femo-
ral shaft, this association does not prove causation. These 
atypical fractures are characterised by unique clinical 
features (prodromal pain and bilaterality) and unique 
Incomplete fracture Complete fracture
Atypical femoral fracture diagnosed
Pain present: Asymptomatic:
–  Intramedullary nailing –  MRI surveillance
–  Minimal weight-bearing until
    MRI shows no bone oedema
–  Discontinue bisphosphonate
–  Check calcium and vitamin D levels +/− supplement
–  Consider Teriparatide
Intramedullary nailing
Fig. 3
Flow chart showing treatment pathway for bisphosphonate-related atypical fractures of the femur (data used to create figure taken from Shane et al27).
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radiographic features (transverse or short oblique orienta-
tion, absence of comminution, cortical thickening, stress 
fracture or stress reaction and delayed healing). It must be 
emphasised that bisphosphonates are vital drugs for the 
prevention of common osteoporotic fractures, and atypi-
cal fractures are rare. The decision to terminate bisphos-
phonate therapy after five years is still a controversial one, 
though patients with a low risk of fractures seem unlikely 
to benefit from treatment beyond this period.
once an atypical fracture occurs, bisphosphonates 
must be stopped, and patients should receive daily cal-
cium and vitamin D supplementation. Fixation should be 
performed using intramedullary nailing, with post-oper-
ative teriparatide commenced to augment healing. 
large-scale data gathering should aid the identification of 
any subpopulations at particular risk of atypical fractures, 
and guide treatment and surveillance strategies. 
Physicians and patients should be made aware of the 
possibility of aFFs and of the potential for bilaterality. 
Future research should facilitate increased surveillance, 
help to establish the true incidence of, and risk factors for, 
these fractures, and finally include studies to address 
their surgical and medical management.
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